Stockscreener 앱 받기
52.31
5.08%
-2.80
Jyong Biotech Ltd 주식(MENS)의 최신 뉴스
Jyong Biotech (NASDAQ:MENS) Shares Gap UpWhat's Next? - MarketBeat
Jyong Biotech (NASDAQ:MENS) Sets New 12-Month HighStill a Buy? - MarketBeat
These Were the 5 Top-Performing Stocks in the Nasdaq Composite in August 2025 - The Motley Fool
Jyong Biotech shares rise 1.06% premarket after being included in a stock market index. - AInvest
Experts discuss the transformative potential of AI for BPH - Urology Times
Jennifer Robles, MD, on future advancements in HoLEP - Urology Times
Jyong Biotech to present clinical data from studies of BOTRESO, MCS-8 - MSN
Jyong Biotech (NASDAQ:MENS) Stock Price Down 6.7%What's Next? - MarketBeat
Jyong Biotech shares rise 1.83% after-hours after participating in the 22nd Urological Association of Asia Congress. - AInvest
Jyong Biotech shares fall 1.93% after-hours following participation in the 22nd Urological Association of Asia Congress. - AInvest
Jyong Biotech Ltd. Participated in the 22nd Urological - GlobeNewswire
Breakthrough: Taiwan's First FDA Phase 3 Botanical Drug BOTRESO Shows Promise in $9.8B BPH Market - Stock Titan
Jyong Biotech (NASDAQ:MENS) Shares Up 10.5%Here's What Happened - MarketBeat
Biopharma IPO drought continues: chance of rain expected? - BioWorld MedTech
Jyong Biotech (NASDAQ:MENS) Shares Gap DownTime to Sell? - MarketBeat
Jyong Biotech (NASDAQ:MENS) Hits New 12-Month HighStill a Buy? - MarketBeat
Jyong Biotech (NASDAQ:MENS) Stock Price Down 12.3%What's Next? - MarketBeat
Jyong Biotech's Plant‑Based Pipeline Targets Huge Markets But Risks Remain - Seeking Alpha
Jyong Biotech Ltd.'s Quiet Period Will End on July 28th (NASDAQ:MENS) - MarketBeat
Jyong Biotech Ltd. shares rise 6.64% intraday as SK Hynix reports Q2 2025 earnings. - AInvest
Jyong Biotech Ltd. Completes Nasdaq IPO and Showcases MCS®-2 at BIO 2025 International Convention - Nasdaq
Jyong Biotech Completes Nasdaq IPO, Participates in BIO 2025 Convention. - AInvest
Jyong Biotech Ltd. Rings Nasdaq Bell and Participates at the BIO 2025 International Convention - GlobeNewswire
Taiwan's Jyong Biotech Takes On $9.8B BPH Market With Revolutionary Plant-Based Treatment After Nasdaq IPO - Stock Titan
Jyong Biotech Ltd.’s Quiet Period Set To Expire on July 28th (NASDAQ:MENS) - Defense World
Biopharma financings total $28.7B in H1, down 59% from 2024 - BioWorld MedTech
Jyong Biotech shares rise 3.85% in premarket after rating upgrade and CEO's Nasdaq bell ringing. - AInvest
Yong Biotech Ltd (Nasdaq:MENS) Marks Milestone at Nasdaq Composite MarketSite - Kalkine Media
Jyong Biotech Ltd. Rings the Closing Bell - Nasdaq
Pre-market Movers: BGLC, ATAI, GOVX, SNGX... - RTTNews
Jyong Biotech shares fall 4.92% in after-hours following a 34.80% surge post-Nasdaq listing and 11.04% gain over the past five days. - AInvest
Jyong Biotech shares rise 2.11% intraday as biotech sector gains and company completes $20M IPO. - AInvest
Jyong Biotech shares rise 11.82% intraday after successful $20 million IPO and addition to Nasdaq Composite Index. - AInvest
Jyong’s $20M US IPO to help refile NDA of urological botanic drug - BioWorld MedTech
Jyong Biotech Soars 11.13% Post $20M IPO - AInvest
MENSJyong Biotech Ltd. Latest Stock News & Market Updates - Stock Titan
Jyong Biotech Plunges 10.98% Despite IPO Surge - AInvest
Taiwan’s Jyong Biotech doubles in value on Nasdaq debut - Investing.com
Taiwan's Jyong Biotech Makes Nasdaq Debut: $20M IPO Targets Breakthrough in Urinary Disease Treatment - Stock Titan
Amy Krambeck, MD, on innovation and building strong programs in endourology - Urology Times
Amy E. Krambeck, MD, on patient selection for HoLEP - Urology Times
Jyong Biotech Seeks US IPO On Thin Capitalization And Uphill Regulatory Battle (MENS) - Seeking Alpha
MENS IPO NewsUrinary disease biotech Jyong Biotech sets terms for $19 million US IPO - renaissancecapital.com
Expert on Aquablation’s comparable long-term outcomes in prostates of different sizes - Urology Times
Ravi Munver, MD, discusses the versatility of Aquablation treatment for BPH - Urology Times
Dr. Das on his experience with HoLEP for treating BPH - Urology Times
Commercial-ready Taiwanese biotech developing therapies for urinary diseases. - renaissancecapital.com
Study assesses Rezum therapy in large prostates - Urology Times
JYB IPO NewsUrinary disease biotech Jyong Biotech withdraws $40 million US IPO - renaissancecapital.com
Dr. Elterman on the new wave of BPH stents - Urology Times
1.40%
자본화:
|
볼륨(24시간):